MedTrace Logo

The TearAD Study: Tear Biomarkers for Alzheimer's Disease (AD) Screening and Diagnosis

NCT05655793 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-03-13

No results posted yet for this study

Summary

The goal of this observational longitudinal study is to investigates whether tear fluid is a non-invasive source of biomarkers for Alzheimer's disease. The main aim of the study is to evaluate diagnostic accuracy measures (sensitivity and specificity) of tear and retinal biomarkers to discriminate individuals with and without neurodegeneration.

Tear fluid from participants will be collected non-invasively with Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes. Additionally, standard, ultra-wide field and cross-sectional retinal images will be obtained.

Conditions

  • Alzheimer Disease

Interventions

DIAGNOSTIC_TEST

Tear Fluid collection (Schirmer's strip)

Tear fluid will be collected non-invasively form all participants with the use of Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes.

DIAGNOSTIC_TEST

Retinal imaging

The retina from all participants will be visualised with the use of a standard (Clarus 700 Zeiss), ultra-wide field (Optos), and cross-sectional (Optical Coherence Tomography) retinal images.

Sponsors & Collaborators

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • Marlies Gijs, PhD · Maastricht University Medical Center

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-09
Primary Completion
2025-07-01
Completion
2025-07-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05655793 on ClinicalTrials.gov